Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 12/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938459 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29229785 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL25852251 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL254518 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3644807 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16883761 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL500069 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL30882856 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL21921819 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10212409 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634970-B1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LTD (IN) | 2023-07-19 | — | — | EP | disclosed |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | LAURUS LABS LIMITED (IN) | 2021-06-29 | — | — | US | disclosed |
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LIMITED (IN) | 2020-04-30 | — | — | US | disclosed |
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED (IN) | 2019-07-04 | — | — | US | disclosed |
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9914688-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914688-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914688-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1828216-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070004648-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | HIMMELSBACH FRANK | 2007-01-04 | — | — | US | disclosed |
| US-20070004648-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | HIMMELSBACH FRANK | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2488/4885 |
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1915/4885 |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
| US-20070004648-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, GYS2, UGT2B7 | SLC5A2 7/4885SLC5A1 6/4885ADRA2A 321/4885 |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.